Drug Profile
Research programme: cancer therapeutics - Glactone Pharma
Alternative Names: GPA 500; GPA512; GPA700-BU; GPB730Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Glactone Pharma
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Prostate cancer
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Prostate cancer in Sweden (PO) (Glactone Pharma website, October 2023)
- 03 Oct 2023 Discontinued for Cancer in Sweden (PO) (Glactone Pharma website, October 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Prostate-cancer in Sweden (PO)